Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.

Authors Lynette M. Sholl, MD, FCAP* Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts Aleodor Andea, MD, MBA, FCAP Department of Pathology, University of Michigan Hospitals, Ann Arbor, Michigan Julia Bridge, MD, FCAP Department of Pathology, University of Nebraska Medical Center, Omaha, Nebraska Liang Cheng, MD, FCAP Department of Pathology, Indiana University, Indianapolis, Indiana Michael A. Davis MD, PhD Departments of Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas Mani Ehteshami, MD, MS, FCAP Newport Coast Pathology Inc, Newport Beach, California Tara C. Gangadhar, MD Department of Medicine and the Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Suzanne Kamel-Reid, PhD, FACMG Department of Pathology, The University Health Network/Princess Margaret Cancer Center, Toronto, Ontario Alexander Lazar, MD, PhD, FCAP Departments of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas Kirtee Raparia, MD, FCAP Department of Pathology, Northwestern University, Chicago, Illinois Alan Siroy, MD, MPH Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas Kim Watson, CTR Cancer Registry Consultant, Sioux Falls, South Dakota

[1]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[2]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[3]  Liang Cheng,et al.  Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. , 2014, Human pathology.

[4]  A. Lazar,et al.  Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma , 2013, Cancer.

[5]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Bastian,et al.  Targeting activated KIT signaling for melanoma therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Flaherty,et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. O'toole,et al.  BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.

[9]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[10]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[11]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[12]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[13]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[14]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Wisell,et al.  Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma , 2013 .

[16]  J. Stockman KIT as a Therapeutic Target in Metastatic Melanoma , 2013 .

[17]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .